Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca drug for rare disease shows promise in flushing copper build-up

Published 26/08/2021, 08:13
Updated 26/08/2021, 08:15
© Reuters.

© Reuters.

(Reuters) - AstraZeneca (NASDAQ:AZN) said on Thursday a late-stage trial showed its medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues compared with standard care.

The treatment, developed by the drugmaker's recently acquired Alexion (NASDAQ:ALXN) rare diseases unit, was being tested for Wilson disease, a genetic condition in which the body's ability to remove excess copper is compromised.

The experimental oral medicine taken once-daily could provide a less invasive option for patients who are typically given treatments which involve injecting a metal removing solution into the blood or zinc therapy.

"As we advance this first innovation in Wilson disease treatment in more than 30 years, we will continue to follow these patients long term to further assess clinical impact on disease symptoms," Alexion Chief Executive Officer Marc Dunoyer said.

© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021.  REUTERS/Rachel Wisniewski/File Photo

Copper build-up can cause liver disease and psychiatric or neurological symptoms, such as personality changes, tremors and difficulty in walking, swallowing or talking.

The study met the main goal of improvement in the daily mean copper mobilised from tissues over a period of 48 weeks. The treatment has been given an "Orphan Drug" status in the United States and European Union to help speed up development.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.